Paper · 34839261
Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro.
Huang HC and 21 others. EBioMedicine, 2021. Cited by 55 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. Papers, record 34839261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34839261
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzamides | Major topic |
| Glycosylation | Major topic |
| Hexosyltransferases | Major topic |
| Membrane Proteins | Major topic |
| Sulfonamides | Major topic |
| Virus Internalization | Major topic |
| COVID-19 Drug Treatment | Major topic |
| A549 Cells | |
| Animals | |
| Antibodies, Neutralizing | |
| Antibodies, Viral | |
| Cell Line | |
| HEK293 Cells | |
| Humans | |
| Mice | |
| Mice, Inbred C57BL | |
| SARS-CoV-2 | |
| Spike Glycoprotein, Coronavirus |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 55 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,957,879 | TRAP complex is essential for coronavirus replication and glycoprotein biogeneses. | EMBO Rep | 2026 | https://conductscience.org/library/papers/42957879 | PubMed |
| 42,903,504 | Targeted protein editing technique in living mammalian cells by peptide-fused PNGase. | Hlife | 2024 | https://conductscience.org/library/papers/42903504 | PubMed |
| 41,910,405 | Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. | J Virol | 2026 | https://conductscience.org/library/papers/41910405 | PubMed |
| 41,743,132 | Rewriting the viral script: post-translational modifications orchestrating SARS-CoV-2 pathogenesis and immune evasion. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41743132 | PubMed |
| 41,295,693 | G2c-Lineage Dominance and S1 Epitope-Glycan Drift of Porcine Epidemic Diarrhea Virus in Guangdong Province, China, 2022-2024. | Vet Sci | 2025 | https://conductscience.org/library/papers/41295693 | PubMed |
| 40,431,537 | Isolation and Characterization of Porcine Epidemic Diarrhea Virus G2c Strains Circulating in China from 2021 to 2024. | Vet Sci | 2025 | https://conductscience.org/library/papers/40431537 | PubMed |
| 40,372,436 | Shared host genetic landscape of respiratory viral infection. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40372436 | PubMed |
| 40,295,734 | Conserved role of spike S2 domain N-glycosylation across betacoronaviruses. | Npj Viruses | 2025 | https://conductscience.org/library/papers/40295734 | PubMed |
| 40,035,514 | Changes in the motifs in the D0 and SD2 domains of the S protein drive the evolution of virulence in enteric coronavirus porcine epidemic diarrhea virus. | J Virol | 2025 | https://conductscience.org/library/papers/40035514 | PubMed |
| 39,402,214 | Restoring protein glycosylation with GlycoShape. | Nat Methods | 2024 | https://conductscience.org/library/papers/39402214 | PubMed |
1 to 10 of 45
See all 45 cited byGenes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACE2 | 59,272 | PubTator's text mining | https://conductscience.org/library/genes/59272 | NCBI Gene |
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTSB | 1,508 | PubTator's text mining | https://conductscience.org/library/genes/1508 | NCBI Gene |
| DDOST | 1,650 | PubTator's text mining | https://conductscience.org/library/genes/1650 | NCBI Gene |
| GAPDH | 2,597 | PubTator's text mining | https://conductscience.org/library/genes/2597 | NCBI Gene |
| NFKB1 | 4,790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| NFKBIA | 4,792 | PubTator's text mining | https://conductscience.org/library/genes/4792 | NCBI Gene |
| OGA | 10,724 | PubTator's text mining | https://conductscience.org/library/genes/10724 | NCBI Gene |
| STT3A | 3,703 | PubTator's text mining | https://conductscience.org/library/genes/3703 | NCBI Gene |
| STT3B | 201,595 | PubTator's text mining | https://conductscience.org/library/genes/201595 | NCBI Gene |
1 to 10 of 12
See all 12 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34839261
GET https://conductscience.org/api/papers/v1/34839261/authors?page=2